Astellas’ Half-Year Revenue Up Nearly 6% on Bullish Xtandi

Astellas Pharma reported on October 29 that its group revenue rose nearly 6%, buoyed by the robust performance of its flagship cancer drug Xtandi (enzalutamide). Net profit slipped, however, due to increases in SGA costs and R&D spending as well...read more